Clinical Trials

Study Title:
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

For more information about the trial above please contact the study team:

Principal Investigator, Brian Hess, at hessbr@musc.edu.

Study Coordinator, Sarah Britton, at brittosa@musc.edu, or please call +1 843-792-8856.

Trial opened at the following institutions: Medical University of South Carolina